Paul Matteis
Stock Analyst at Stifel Nicolaus
(4.75)
# 622
Out of 4,361 analysts
718
Total ratings
51.5%
Success rate
14.9%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Reiterated: Buy | $28 → $36 | $27.34 | +31.68% | 4 | Jun 2, 2026 | |
| IMUX Immunic | Maintained: Buy | $25 | $14.64 | +70.77% | 3 | May 28, 2026 | |
| SPTX Seaport Therapeutics | Initiated Coverage: Buy | $30 | $17.21 | +74.32% | 1 | May 26, 2026 | |
| SION Sionna Therapeutics | Maintained: Buy | $55 | $36.48 | +50.77% | 4 | May 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Hold | $68 | $53.32 | +27.53% | 44 | May 24, 2026 | |
| NGNE Neurogene | Reiterated: Buy | $46 | $26.14 | +75.98% | 23 | May 13, 2026 | |
| NMRA Neumora Therapeutics | Maintained: Hold | $3 | $1.75 | +71.43% | 10 | May 12, 2026 | |
| LXEO Lexeo Therapeutics | Maintained: Buy | $21 → $17 | $4.51 | +276.94% | 8 | May 12, 2026 | |
| RAPP Rapport Therapeutics | Maintained: Buy | $56 | $34.90 | +60.46% | 10 | May 12, 2026 | |
| ALKS Alkermes | Maintained: Buy | $42 → $45 | $41.32 | +8.91% | 57 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $89 → $86 | $52.30 | +64.44% | 27 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $42 → $27 | $26.94 | +0.22% | 21 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $131 → $133 | $84.35 | +57.68% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 → $28 | $12.38 | +126.17% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $20.89 | +14.89% | 48 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $188 | $154.84 | +21.42% | 54 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $466 | $425.09 | +9.62% | 41 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $28 | $26.76 | +4.63% | 25 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $83 → $86 | $72.97 | +17.86% | 32 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $22.86 | +31.23% | 2 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $214 | $188.83 | +13.33% | 50 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.45 | +727.59% | 17 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 | $18.71 | +76.38% | 10 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 | $19.35 | +111.89% | 28 | Mar 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $40 | $27.02 | +48.04% | 3 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $14 | $13.33 | +5.03% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 | $24.87 | +28.67% | 10 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $0.58 | +72.41% | 7 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $508 → $444 | $286.12 | +55.18% | 46 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.95 | - | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.37 | +321.94% | 9 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 → $36 | $17.24 | +108.82% | 26 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.02 | n/a | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $11.20 | n/a | 11 | Jun 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $5.69 | n/a | 13 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $20 | $68.00 | n/a | 4 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.0001 | n/a | 1 | Aug 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $20 | $0.0001 | n/a | 4 | Mar 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.42 | n/a | 1 | Nov 23, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.57 | n/a | 4 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $15.58 | n/a | 5 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $0.0003 | n/a | 3 | May 19, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 → $7 | $1.31 | n/a | 2 | May 6, 2016 |
MapLight Therapeutics
Jun 2, 2026
Reiterated: Buy
Price Target: $28 → $36
Current: $27.34
Upside: +31.68%
Immunic
May 28, 2026
Maintained: Buy
Price Target: $25
Current: $14.64
Upside: +70.77%
Seaport Therapeutics
May 26, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $17.21
Upside: +74.32%
Sionna Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $55
Current: $36.48
Upside: +50.77%
BioMarin Pharmaceutical
May 24, 2026
Maintained: Hold
Price Target: $68
Current: $53.32
Upside: +27.53%
Neurogene
May 13, 2026
Reiterated: Buy
Price Target: $46
Current: $26.14
Upside: +75.98%
Neumora Therapeutics
May 12, 2026
Maintained: Hold
Price Target: $3
Current: $1.75
Upside: +71.43%
Lexeo Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $21 → $17
Current: $4.51
Upside: +276.94%
Rapport Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $56
Current: $34.90
Upside: +60.46%
Alkermes
May 8, 2026
Maintained: Buy
Price Target: $42 → $45
Current: $41.32
Upside: +8.91%
May 8, 2026
Maintained: Buy
Price Target: $89 → $86
Current: $52.30
Upside: +64.44%
May 8, 2026
Downgraded: Hold
Price Target: $42 → $27
Current: $26.94
Upside: +0.22%
May 8, 2026
Maintained: Buy
Price Target: $131 → $133
Current: $84.35
Upside: +57.68%
May 8, 2026
Maintained: Buy
Price Target: $29 → $28
Current: $12.38
Upside: +126.17%
May 7, 2026
Reiterated: Hold
Price Target: $24
Current: $20.89
Upside: +14.89%
May 6, 2026
Maintained: Buy
Price Target: $188
Current: $154.84
Upside: +21.42%
May 5, 2026
Maintained: Hold
Price Target: $466
Current: $425.09
Upside: +9.62%
May 5, 2026
Reiterated: Buy
Price Target: $14 → $28
Current: $26.76
Upside: +4.63%
Apr 30, 2026
Maintained: Hold
Price Target: $83 → $86
Current: $72.97
Upside: +17.86%
Apr 24, 2026
Maintained: Buy
Price Target: $30
Current: $22.86
Upside: +31.23%
Apr 4, 2026
Maintained: Buy
Price Target: $214
Current: $188.83
Upside: +13.33%
Apr 4, 2026
Maintained: Buy
Price Target: $12
Current: $1.45
Upside: +727.59%
Apr 2, 2026
Maintained: Buy
Price Target: $33
Current: $18.71
Upside: +76.38%
Mar 29, 2026
Maintained: Buy
Price Target: $41
Current: $19.35
Upside: +111.89%
Mar 27, 2026
Reiterated: Buy
Price Target: $35 → $40
Current: $27.02
Upside: +48.04%
Mar 25, 2026
Reiterated: Buy
Price Target: $11 → $14
Current: $13.33
Upside: +5.03%
Mar 6, 2026
Reiterated: Buy
Price Target: $32
Current: $24.87
Upside: +28.67%
Feb 13, 2026
Maintained: Hold
Price Target: $1
Current: $0.58
Upside: +72.41%
Feb 12, 2026
Reiterated: Buy
Price Target: $508 → $444
Current: $286.12
Upside: +55.18%
Dec 22, 2025
Rated: Hold
Price Target: n/a
Current: $1.95
Upside: -
Dec 16, 2025
Reiterated: Buy
Price Target: $10
Current: $2.37
Upside: +321.94%
Dec 15, 2025
Maintained: Buy
Price Target: $39 → $36
Current: $17.24
Upside: +108.82%
Sep 19, 2024
Rated: Hold
Price Target: n/a
Current: $9.02
Upside: n/a
Jun 3, 2023
Maintained: Buy
Price Target: $5
Current: $11.20
Upside: n/a
May 12, 2022
Reiterated: Hold
Price Target: $3
Current: $5.69
Upside: n/a
Feb 28, 2022
Downgraded: Hold
Price Target: $11 → $20
Current: $68.00
Upside: n/a
Aug 16, 2017
Initiated Coverage: Buy
Price Target: $18
Current: $0.0001
Upside: n/a
Mar 10, 2017
Reiterated: Buy
Price Target: $14 → $20
Current: $0.0001
Upside: n/a
Nov 23, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.42
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.57
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: $29
Current: $15.58
Upside: n/a
May 19, 2016
Maintained: Buy
Price Target: $11
Current: $0.0003
Upside: n/a
May 6, 2016
Reiterated: Hold
Price Target: $14 → $7
Current: $1.31
Upside: n/a